EP Patent

EP3011976A1 — 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents

Assigned to Deutsches Krebsforschungszentrum DKFZ · Expires 2016-04-27 · 10y expired

What this patent protects

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.

USPTO Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.

Drugs covered by this patent

Patent Metadata

Patent number: EP3011976A1
Jurisdiction: EP
Classification: —
Expires: 2016-04-27
Drug substance claim: No
Drug product claim: No
Assignee: Deutsches Krebsforschungszentrum DKFZ
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.